BIOMAT Database Logo BIOMAT Database Logo

[Combined chemotherapy: prednisone, cytosine arabinose and vincristine in the treatment of acute non-lymphoblastic leukemia in the adult]. 1980

A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Treatment of adult acute lymphoblastic leukemia with cytosine arabinoside, vincristine, and prednisone.
September 1978, Cancer treatment reports,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
[Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone].
January 1984, Sangre,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL).
January 1977, Medical and pediatric oncology,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Treatment of adult acute lymphoblastic leukemia with adriamycin, vincristine, and prednisone.
January 1983, Medical and pediatric oncology,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.
February 1995, Annals of hematology,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Continuous-infusion cyclophosphamide plus vincristine, cytosine-arabinoside and prednisone for refractory acute lymphoblastic leukemia in adults.
January 1991, Haematologica,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
June 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Alternating pulses of vincristine-prednisone with cytarabine-cyclophosphamide versus vincristine-prednisone in the maintenance therapy of acute lymphoblastic leukemia.
April 1984, Cancer treatment reports,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP).
January 1981, Medical and pediatric oncology,
A Avilés-Miranda, and L M Monroy-Arellano, and G Conte-Lanza, and M R Morales-Polanco, and J Pizzuto-Chávez
Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
September 1996, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Copied contents to your clipboard!